Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
暂无分享,去创建一个
W. Gregory | P. Johnson | W. Qian | R. Rudd | N. Gower | T. Eisen | S. Spiro | J. Littler | E. Rankin | P. Harper | M. Hatton | S. M. Lee | P. Harper | L. James | W. Martin | Robin M. Rudd | Stephen G. Spiro | Tim Eisen | J.A.H. Littler | Matthew Hatton | Peter Johnson | W.M.C. Martin | Walter M Gregory | Wendi Qian | Siow Ming Lee | Matthew Q. Hatton | W. Gregory | T. Eisen | S. Spiro
[1] M. Gore. Carboplatin equals cisplatin: but how do I prescribe it? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Ranson,et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma , 2003, Cancer.
[3] G. Scagliotti,et al. O-239 Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data , 2003 .
[4] J. Bogaerts,et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[6] P. Fayers,et al. Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party. , 2000, Statistics in medicine.
[7] L. Einhorn,et al. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. , 1999, American journal of clinical oncology.
[8] S. Barni,et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Souhami,et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Ettinger,et al. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. , 1999, The oncologist.
[11] E. Vonesh,et al. Linear and Nonlinear Models for the Analysis of Repeated Measurements , 1996 .
[12] J. Carmichael,et al. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. , 1996, Seminars in oncology.
[13] G. Peters,et al. Synergistic interaction between cisplatin and gemcitabine in vitro. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] R. Souhami,et al. Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Davidian,et al. Nonlinear Models for Repeated Measurement Data , 1995 .
[16] L. Crinò,et al. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] P. Diggle. Analysis of Longitudinal Data , 1995 .
[18] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[19] M. H. Gault,et al. Predicting glomerular function from adjusted serum creatinine. , 1992, Nephron.
[20] Douglas G. Altman,et al. Practical statistics for medical research , 1990 .
[21] R. Souhami,et al. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. , 1990, European journal of cancer.
[22] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] L. Hertel,et al. Synthesis of 2-Deoxy-2,2-difluoro-D-ribose and 2-Deoxy-2,2-difluoro-D-ribofuranosyl Nucleosides. , 1988 .
[24] P. Zatloukal,et al. Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial , 2003 .
[25] A. Gregor,et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Kaasa,et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. , 1994, European journal of cancer.